 Mario Enrico Canonico
Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Coronary Syndrome | 6 | 2023 | 254 | 1.950 |
Why?
| | Percutaneous Coronary Intervention | 8 | 2023 | 445 | 1.430 |
Why?
| | ST Elevation Myocardial Infarction | 2 | 2022 | 50 | 0.880 |
Why?
| | Anticholesteremic Agents | 1 | 2023 | 129 | 0.750 |
Why?
| | Venous Thrombosis | 1 | 2022 | 142 | 0.680 |
Why?
| | Mobile Applications | 1 | 2022 | 140 | 0.680 |
Why?
| | Coronavirus | 1 | 2020 | 40 | 0.670 |
Why?
| | Blood Platelets | 2 | 2022 | 323 | 0.640 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 371 | 0.640 |
Why?
| | Platelet Aggregation Inhibitors | 8 | 2023 | 395 | 0.630 |
Why?
| | Thrombosis | 1 | 2022 | 293 | 0.620 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 333 | 0.610 |
Why?
| | Venous Thromboembolism | 1 | 2022 | 231 | 0.610 |
Why?
| | Coronavirus Infections | 2 | 2020 | 325 | 0.610 |
Why?
| | Sex Characteristics | 1 | 2023 | 633 | 0.610 |
Why?
| | Precision Medicine | 1 | 2021 | 335 | 0.570 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2022 | 486 | 0.570 |
Why?
| | Peripheral Arterial Disease | 1 | 2023 | 381 | 0.550 |
Why?
| | Heart Failure | 3 | 2022 | 1955 | 0.500 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 896 | 0.470 |
Why?
| | Neoplasms | 3 | 2022 | 2082 | 0.450 |
Why?
| | Pandemics | 2 | 2020 | 1308 | 0.420 |
Why?
| | Anticoagulants | 4 | 2022 | 548 | 0.340 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2088 | 0.320 |
Why?
| | Purinergic P2Y Receptor Antagonists | 4 | 2023 | 61 | 0.310 |
Why?
| | Humans | 29 | 2023 | 113531 | 0.290 |
Why?
| | Atrial Fibrillation | 2 | 2021 | 325 | 0.280 |
Why?
| | Betacoronavirus | 2 | 2020 | 246 | 0.280 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2021 | 361 | 0.280 |
Why?
| | Stroke Volume | 4 | 2021 | 510 | 0.250 |
Why?
| | Coronary Artery Disease | 2 | 2021 | 610 | 0.250 |
Why?
| | Coronary Angiography | 4 | 2021 | 307 | 0.230 |
Why?
| | Adenosine Monophosphate | 2 | 2023 | 49 | 0.230 |
Why?
| | Morphine Derivatives | 1 | 2023 | 13 | 0.220 |
Why?
| | Tablets | 1 | 2023 | 35 | 0.220 |
Why?
| | Platelet Aggregation | 2 | 2022 | 90 | 0.220 |
Why?
| | Subtilisin | 1 | 2023 | 3 | 0.220 |
Why?
| | Proprotein Convertases | 1 | 2023 | 14 | 0.210 |
Why?
| | Ventricular Function, Left | 3 | 2021 | 469 | 0.210 |
Why?
| | Proprotein Convertase 9 | 1 | 2023 | 61 | 0.210 |
Why?
| | Atrial Remodeling | 1 | 2022 | 8 | 0.200 |
Why?
| | Adenosine | 1 | 2023 | 202 | 0.200 |
Why?
| | Hypertension | 2 | 2020 | 1051 | 0.190 |
Why?
| | Glucosephosphate Dehydrogenase Deficiency | 1 | 2021 | 13 | 0.190 |
Why?
| | Bundle-Branch Block | 1 | 2021 | 28 | 0.190 |
Why?
| | Cholesterol, LDL | 1 | 2023 | 306 | 0.190 |
Why?
| | Cardiotoxicity | 1 | 2021 | 27 | 0.190 |
Why?
| | Drug Compounding | 1 | 2021 | 89 | 0.180 |
Why?
| | Prevalence | 3 | 2021 | 2244 | 0.180 |
Why?
| | Treatment Outcome | 7 | 2023 | 9006 | 0.180 |
Why?
| | Cardiology | 1 | 2023 | 260 | 0.180 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2023 | 223 | 0.180 |
Why?
| | Coronary Stenosis | 1 | 2020 | 38 | 0.170 |
Why?
| | Coronary Occlusion | 1 | 2020 | 18 | 0.170 |
Why?
| | Drug-Eluting Stents | 1 | 2020 | 62 | 0.170 |
Why?
| | Radial Artery | 2 | 2021 | 65 | 0.170 |
Why?
| | Shock, Cardiogenic | 1 | 2020 | 54 | 0.170 |
Why?
| | Myocarditis | 1 | 2021 | 92 | 0.170 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2021 | 146 | 0.170 |
Why?
| | Angioplasty, Balloon | 1 | 2021 | 88 | 0.170 |
Why?
| | Heart Arrest | 1 | 2023 | 293 | 0.160 |
Why?
| | Students, Medical | 1 | 2023 | 260 | 0.160 |
Why?
| | Pulmonary Embolism | 1 | 2020 | 181 | 0.150 |
Why?
| | Hepatitis C, Chronic | 1 | 2020 | 150 | 0.150 |
Why?
| | Male | 13 | 2023 | 55112 | 0.150 |
Why?
| | Cardiomyopathies | 1 | 2021 | 296 | 0.150 |
Why?
| | Echocardiography | 4 | 2022 | 563 | 0.150 |
Why?
| | Antibodies, Monoclonal | 1 | 2023 | 1236 | 0.140 |
Why?
| | Middle Aged | 8 | 2021 | 26552 | 0.130 |
Why?
| | Femoral Artery | 1 | 2016 | 165 | 0.120 |
Why?
| | Heart Ventricles | 1 | 2020 | 710 | 0.120 |
Why?
| | Female | 9 | 2023 | 59115 | 0.110 |
Why?
| | Blood Pressure | 1 | 2020 | 1521 | 0.110 |
Why?
| | Risk Factors | 2 | 2023 | 8606 | 0.100 |
Why?
| | Cardiac Catheterization | 1 | 2016 | 540 | 0.100 |
Why?
| | Italy | 2 | 2023 | 92 | 0.100 |
Why?
| | Aged | 7 | 2022 | 18944 | 0.090 |
Why?
| | Registries | 3 | 2023 | 1762 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 1725 | 0.080 |
Why?
| | Administration, Oral | 2 | 2021 | 719 | 0.080 |
Why?
| | Prognosis | 3 | 2021 | 3318 | 0.080 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 230 | 0.080 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 944 | 0.070 |
Why?
| | United States | 1 | 2023 | 12137 | 0.070 |
Why?
| | Adult | 3 | 2022 | 30245 | 0.070 |
Why?
| | Retrospective Studies | 4 | 2021 | 12504 | 0.050 |
Why?
| | Emergencies | 1 | 2023 | 144 | 0.050 |
Why?
| | Prasugrel Hydrochloride | 1 | 2022 | 19 | 0.050 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2021 | 36 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2022 | 94 | 0.050 |
Why?
| | Heart Atria | 1 | 2022 | 107 | 0.050 |
Why?
| | Gadolinium | 1 | 2021 | 73 | 0.050 |
Why?
| | Vitamin K | 1 | 2021 | 41 | 0.050 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2020 | 101 | 0.040 |
Why?
| | Contrast Media | 1 | 2021 | 346 | 0.040 |
Why?
| | Hepacivirus | 1 | 2020 | 228 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2020 | 231 | 0.040 |
Why?
| | Acute Disease | 1 | 2021 | 885 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2022 | 652 | 0.040 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2020 | 216 | 0.040 |
Why?
| | Aspirin | 1 | 2020 | 325 | 0.040 |
Why?
| | Hemorrhage | 1 | 2022 | 599 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 1822 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 1783 | 0.030 |
Why?
| | Stents | 1 | 2020 | 463 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 1832 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1443 | 0.030 |
Why?
| | Body Mass Index | 1 | 2022 | 1952 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2310 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2530 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 542 | 0.030 |
Why?
| | Patient Safety | 1 | 2016 | 272 | 0.030 |
Why?
| | Cohort Studies | 1 | 2021 | 4880 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 3389 | 0.020 |
Why?
| | Length of Stay | 1 | 2016 | 963 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 2953 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 4400 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1205 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 6189 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 6296 | 0.020 |
Why?
| | Hypertension, Pulmonary | 1 | 2020 | 1733 | 0.020 |
Why?
| | Animals | 1 | 2021 | 31162 | 0.010 |
Why?
|
|
Canonico's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|